Diligence memo · auto-generated · as of July 2, 2026

Puna Bio Corp

Puna Bio Corp looks fair against its niche peers and is active on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Puna Bio Corp operates in Biotech / Pharma, based in SAN FRANCISCO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Puna Bio Corp has raised $20M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $20M on 2025-03-05.

Most recent recorded round closed around 2025-03-05.

Valuation (modeled)modeled

Provath models Puna Bio Corp at approximately $109M (range $42M–$171M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.35× the median modeled value of Series B Biotech / Pharma companies in 2025–2027 (9 peers) — value vs value, same stage and era. Within the normal band (135% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 16 mo ago; this sector typically re-raises about every 15 months.

Raising on or ahead of the sector's normal rhythm.

Comparablesmixed

Capital scale ranks ahead of 76% of Biotech / Pharma peers (227 compared).

Modeled value ranks above 71% of those peers.

Closest niche peers: Inductive Bio, Inc., Wheeler Bio, Inc., Abrexa Pharmaceuticals, Inc., Arpeggio Biosciences, Inc., Vinci Pharmaceuticals, Inc..

Peoplefiled

8 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.